Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Dainippon Ditches Napabucasin, 27 Billion Yen Impairment Loss to Be Incurred in FY2021
Sumitomo Dainippon Pharma will abandon all of its ongoing PI and PII clinical studies of its investigational anticancer agent napabucasin after a flop in a closely watched global PIII study for colorectal cancer. The Osaka drug maker announced the termination…
To read the full story
Related Article
- Sumitomo Dainippon Cuts Operating Profit Outlook on Napabucasin Flop
February 15, 2021
- Napabucasin Fails in PIII for Colorectal Cancer: Sumitomo Dainippon
February 10, 2021
- Sumitomo Dainippon’s Napabucasin Flops in Pancreatic Cancer Trial
July 3, 2019
BUSINESS
- Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
March 5, 2026
- Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
March 5, 2026
- Ono Partners with Congruence on Neurology, Immunology Drug Discovery
March 5, 2026
- Nxera Files for Daridorexant Approval in South Korea
March 5, 2026
- Sawai Prevails in Patent Suit against Viatris over Amitiza Generic
March 5, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…